Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA has appointed Jonathan Dickinson as the new CEO and Chairman of the Executive Board, beginning November 1, 2024. Dickinson, who brings extensive biotech and pharmaceutical experience, succeeds interim CEO Hervé Brailly, who will remain in an advisory role to ensure a smooth transition. This leadership change is expected to drive the company’s innovative immuno-oncology pipeline forward, potentially impacting its stock performance.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
